UK markets open in 1 hour 38 minutes

Allergy Therapeutics plc (AGY.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
19.250.00 (0.00%)
At close: 04:35PM BST
Full screen
Previous close19.25
Open19.68
Bid18.00 x 0
Ask0.00 x 0
Day's range19.68 - 20.50
52-week range16.00 - 40.50
Volume549
Avg. volume36,075
Market cap123.97M
Beta (5Y monthly)1.44
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Interim Results for the six months ended 31 December 2021

    Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou

  • Globe Newswire

    Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022Topline data from first-in-human trial expected in H1 2023Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate 26 January 2022 Allergy Therapeutics

  • Globe Newswire

    Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL

    Allergy Therapeutics plc(“Allergy Therapeutics”, “ATL” or the “Group”) Allergy Therapeutics announces positive top line results from G309 exploratory field trial to evaluate efficacy and safety of Grass MATA MPL Primary endpoint Combined Symptom Medication Score (CSMS) achieved with clinically relevant improvement across both active treatment groups compared to placebo Statistically significant reduction in CSMS seen in both active treatment groups of 29.1% and 36.8% compared to placebo Analysis